Dietary phytoestrogens: Potential selective estrogen enzyme modulators?

Planta Medica

Volumn 71, Issue 4, 2005, Pages 287-294

  Basly, Jean Philippe ^a   Lavier, Marie Chantal Canivenc ^b  

^a UNIVERSITY OF LIMOGES   (France)

^b CEMAGREF   (France)

Author keywords

Aromatase; Endocrine disrupters; Hydroxysteroid dehydrogenases; Phytoestrogens; Sulfatase; Sulfotransferases

Indexed keywords

APIGENIN; AROMATASE; AURANTIIN; BIOCHANIN A; CATECHIN; CHRYSIN; COUMESTROL; DAIDZEIN; DAIDZEIN 4' O SULFATE; DAIDZEIN 4',7 DI O SULFATE; DAIDZEIN 7 O SULFATE; ENTERODIOL; ENTEROLACTONE; ENZYME INHIBITOR; EQUOL; ERIODICTYOL; ERODICTYOL; FLAVONOID; FORMONONETIN; GALLOCATECHIN; GENISTEIN; GENISTEIN 7 O SULFATE; HESPERETIN; ISOFLAVONOID; KAEMPFEROL; LIGNAN DERIVATIVE; LUTEOLIN; NARINGENIN; PHYTOESTROGEN; QUERCETIN; RESVERATROL; SELECTIVE ESTROGEN ENZYME MODULATOR; STEROID; SULFATASE; SULFOTRANSFERASE; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG;

BREAST CANCER; DIET; DOSE RESPONSE; DRUG BINDING SITE; DRUG POTENCY; HUMAN; HUMAN CELL; IC 50; REVIEW; STRUCTURE ACTIVITY RELATION;

BREAST NEOPLASMS; DIETARY SUPPLEMENTS; FEMALE; HUMANS; PHYTOESTROGENS; PHYTOTHERAPY; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 18744389481     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-864092     Document Type: Review

References (89)

1. Brzezinski A, Debi A. Phytoestrogens: the "natural" selective estrogen receptor modulators? Eur J Obstet Gynecol Reprod Biol 1999; 85: 47-51
2. Thijssen JHH. Local biosynthesis and metabolism of estrogens in the human breast. Maturitas 2004; 49: 25-33
3. Chetrite GS, Pasqualini JR. The selective estrogen enzyme modulator (SEEM) in breast cancer. J Steroid Biochem Molec Biol 2001; 76: 95-104
4. Pasqualini JR. The selective estrogen enzyme modulators in breast cancer: a review. Biochim Biophys Acta 2004; 1654: 123-43
5. Diel P, Smolnikar K, Michna H. In vitro systems for the evaluation of the estrogenic activity of natural products. Planta Medica 1999; 65: 197-203
6. Ososki AL, Kenelly EJ. Phytoestrogens: a review of the present state of research. Phytother Res 2003; 17: 845-69
7. Cos P, De Bruyne T, Apers S, Vanden Bergue D, Pieters L, Vlietinck AJ. Phytoestrogens: Recent developments. Planta Medica 2003; 69: 589-99
8. Miksicek RJ. Estrogenic flavonoids: structural requirements for biological activity. Proc Soc Exp Biol Med 1995; 208: 44-50
9. Kuiper GGJM, Lemmen JG, Carlsson B, Corton JC, Safe SH, Van der Saag PT, Van der Burg B, Gustafsson JA. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998; 10: 4252-63
10. Rosenberg-Zand RJ, Jenkins DJA, Diamandis EP. Steroid hormone activity of flavonoids and related compounds. Breast Cancer Res Treat 2000; 62: 35-49
11. Branham WS, Dial SL, Moland RG, Hass BS, Blair RM, Fang H, Shi L, Tong W, Perkins RG, Sheenan DM. Phytoestrogens and mycoestrogens bind to the rat uterine estrogen receptor. J. Nutr 2002; 132: 658-64
12. Zierau O, Gester S, Schwab P, Metz P, Kolba S, Wulf M, Vollmer G. Estrogenic activity of the phytoestrogens naringenin, 6-(1,1-dimethylallyl)- naringenin and 8-prenylnaringenin. Planta Medica 2002; 68: 449-51
13. Diel P, Thomae RB, Caldarelli A, Zierau O, Kolba S, Schmidt S, Schwab P, Metz P, Vollmer G. Regulation of gene expression by 8-prenylnaringenin in uterus and liver of Wistar rats. Planta Medica 2004; 70: 39-44
14. Gehm BD, McAndrews JM, Chien PY, Jameson JL. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA 1997; 94: 14138-43
15. Dixon RA. Phytoestrogens. Annu Rev Plant Biol 2004; 55: 225-61
16. Wang LQ. Mammalian phytoestrogens: enterodiol and enterolactone. J Chromatogr B 2002; 777: 289-309
17. Poirier D, Ciobanu LC, Maltais R. Steroid Sulfatase inhibitors. Exp Opinion Ther Patents 1999; 9: 1083-99
18. Harris RM, Wood DM, Bottomley L, Blagg S, Owen K, Hughes K, Waring RH, Kirk CJ. Phytoestrogens are potent inhibitors of estrogen sulfation: implications for breast cancer risk and treatment. J Clin Endocrinol Metab 2004; 89: 1779-87
19. Wong CK, Keung WM. Daidzein sulfoconjugates are potent inhibitors of sterol sulfatase (EC 3.1.6.2). Biochem Biophys Res Commun 1997; 233: 579-83
20. 3]isoflavone internal standards. Anal Biochem 2002; 309: 58-72
21. Huang Z, Fasco MJ, Kaminsky LS. Inhibition of estrone sulfatase in human liver microsomes by quercetin and other flavonoids. J Steroid Biochem Molec Biol 1997; 63: 9-15
22. Mindich R, Möller G, Adamski J. The role of 17-beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 2004; 218: 7-20
23. Sasano H, Suzuki T, Takeyama J, Utsunomiya H, Ito K, Ariga N, Moriya T. 17-beta-hydroxysteroid dehydrogenase in human breast and endometrial carcinoma. A new development in intracrinology. Oncology 2000; 59: 5-12
24. Oduwole OO, Li Y, Isomaa VV, Mäntyniemi A, Pulkka AE, Sioni Y, Vihko PT. 17β-Hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer. Cancer Res 2004; 64: 7604-9
25. Mäkëlä S, Poutainen M, Kostian ML, Lehtimäki N, Strauss L, Santti R, Vihko R. Inhibition of 17β-hydroxysteroid oxidoreductase by flavonoids in breast and prostate cancer cells. Proc Soc Exp Biol Med 1998; 217: 310-6
26. Le Bail JC, Laroche T, Marre-Fournier F, Habrioux G. Aromatase and 17β-hydroxysteroid dehydrogenase by flavonoids. Cancer Lett 1998; 133: 101-5
27. Le Bail JC, Champavier Y, Chulia A, Habrioux G. Effects of phytoestrogens on aromatase, 3β-hydroxysteroid dehydrogenase Δ5/Δ4 isomerase, 17β-hydroxysteroid dehydrogenase activities and human breast cancer cells. Life Sci 2000; 66: 1281-91
28. Le Bail JC, Pouget C, Fagnere C, Basly JP, Chulia AJ, Habrioux G. Chalcones are potent inhibitors of aromatase and 17β-hydroxysteroid dehydrogenase activities. Life Sci 2001; 68: 751-61
29. Vinh TK, Nicholls PJ, Kirby AJ, Simons C. Evaluation of 7-hydroxy-flavones as inhibitors of oestrone and oestradiol biosynthesis. J Enz Inhib 2001; 16: 417-24
30. Type 1 17β-HSD catalyses the conversion of androstenedione to testosterone but is mainly expressed in the testes and consequently is outside the scope of this review.
31. Krazeisen A, Breitling R, Möller G, Adamski J. Phytoestrogens inhibit human 17beta-hydroxysteroid dehydrogenase type 5. Mol Cell Endocrinol 2001; 171: 151-62
32. Krazeisen A, Breitling R, Möller G, Adamski J. Human 17beta-hydroxysteroid dehydrogenase type 5 is inhibited by dietary flavonoids. Adv Exp Med Biol 2002; 505: 151-61
33. Harada N. Aromatase and intracrinology of estrogen in hormone-dependent tumors. Oncology 1999; 57: 7-16
34. Chetrite GS, Corto-Prieto J, Philippe JC, Wright F. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J Steroid Biochem Molec Biol 2000; 72: 23-7
35. Akhtar M, Calder MR, Corina DL, Wright JN. Mechanistic studies on C-19 demethylation in oestrogen biosynthesis. Biochem J 1982; 201: 569-80
36. Kellis JT, Vickery LE. Inhibition of human estrogen synthetase (aromatase) by flavones. Science 1984; 225: 1032-4
37. Moochhala SM, Loke KH, Das NP. Spectral perturbation of human microsomal cytochrome P-450 by flavonoid binding. Biochem J 1988; 17: 755-62
38. Wang C, Mäkelä T, Hase T, Adlercreutz H, Kurzer MS. Lignans and flavonoids inhibit aromatase enzyme in human preadipocytes. J Steroid Biochem Molec Biol 1994; 50: 205-12
39. Jeong HJ, Shin YG, Kim IH, Pezzuto JM. Inhibition of aromatase activity by flavonoids. Arch Pharm Res 1999; 22: 309-12
40. Stresser DM, Turner SD, McNamara J, Stocker P, Miller VP, Crespi CL, Patten CJ. A high-throughput screen to identify inhibitors of aromatase (CYP19). Anal Biochem 2000; 284: 427-30
41. Sanderson JT, Hordijk J, Denison MS, Springsteel MF, Nantz MH, van den Berg M. Induction and inhibition of aromatase (CYP19) activity by natural and synthetic flavonoid compounds in H295R human adrenocortical carcinoma cells. Toxicol Sci 2004; 82: 70-9
42. Kao YC, Zhou CB, Sherman M, Laughton CA, Chen S. Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: A site-directed mutagenesis study. Environ Health Persp 1998; 106: 85-92
43. Almstrup K, Fernandez MF, Petersen JH, Olea N, Skakkeboæk NE, Leffers H. Dual effects of phytoestrogens result in U-shaped dose-response curves. Environ Health Persp 2002; 110: 743-8
44. Campbell DR, Kurzer MS. Flavonoid inhibition of aromatase enzyme activity in human preadipocytes. J Steroid Biochem Molec Biol 1993; 46: 381-88
45. Satoh K, Sakamoto Y, Ogata A, Nagai F, Mikuriya H, Numazawa M, Yamada K, Aoki N. Inhibition of aromatase activity by green tea extract catechins and their endocrinological effects of oral administration in rats. Food Chem Toxicol 2002; 40: 925-33
46. White EL, Ross LJ, Steele VE, Kelloff GJ, Hill DL. Screening of potential cancer preventing chemicals as aromatase inhibitors in an in vitro assay. Anticancer Res 1999; 19: 1017-20
47. Adlercreutz H, Bannwart C, Wähälä K, Mäkelä T, Brunow G, Hase T, Arosema PJ, Kellis JT, Vickery LE. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. J Steroid Biochem Molec Biol 1993; 44: 147-53
48. Ibrahim AR, Abul-Hajj YJ. Aromatase inhibition by flavonoids. J Steroid Biochem Molec Biol 1990; 34: 257-60
49. Saarinen N, Joshi SC, Ahotupa M, Li X, Ammälä J, Mäkelä S, Santti R. No evidence for the in vivo activity of aromatase-inhibiting flavonoids. J Steroid Biochem Molecul Biol 2001; 78: 231-9
50. Kester MH, Bulduk S, Tibboel D, Meinl W, Glatt H, Falany CN, Coughtrie MW, Bergman A, Safe SH, Kuiper GGJM, Schuur AG, Brouwer A, Visser TJ. Potent inhibition of estrogen sulfotransferase by hydroxylated PCB metabolites: a novel pathway explaining the estrogenic activity of PCBs. Endocrinology 2000; 141: 1897-900
51. Strott CA. Sulfonation and molecular action. Endocrin Rev 2002; 23: 703-732
52. Otake Y, Nolan AL, Walle K, Walle T. Quercetin and resveratrol potently reduce estrogen sulfotransferase activity in normal human mammary epithelial cells. J Steroid Biochem Molec Biol 2000; 73: 265-70
53. Falany JL, Falany CN. Expression of cytosolic sulfotransferases in normal mammary epithelial cells and breast cancer cell lines. Cancer Res 1996; 56: 1551-5
54. Glatt H, Boeing H, Engelke CEH, Ma L, Kuhlow A, Pabel U, Pomplun D, Teubner W, Meinl W. Human cytosolic sulphotransferases: genetics, characteristics, lexicological aspects. Mutation Res 2001; 482: 27-40
55. Eaton EA, Walle UK, Lewis AJ, Hudson T, Wilson AA, Walle T. Flavonoids, potent inhibitors of the human P-form phenolsulfotransferase. Potential role in drug metabolism and chemoprevention. Drug Metab Dispos 1996; 24: 232-7
56. Ghazali RA, Waring RH. The effects of flavonoids on human phenolsulphotransferases: potential in drug metabolism and chemoprevention. Life Sci 1999; 65: 1625-32
57. Kirk CJ, Harris RM, Wood DM, Waring RH, Hughes PJ. Do dietary phytoestrogens influence susceptibility to hormone-dependent cancer by disrupting the metabolism of endogenous oestrogens? Biochem Soc Trans 2001; 29: 209-16
58. Manach C, Scalbert A, Morand C, Remesy C, Jimenez L. Popyphenols: food sources and bioavailability. Am J Clin Nutr 2004; 79: 727-47
59. Zhu M, Chen Y, Li RC. Oral absorption and bioavailability of tea catechins. Planta Medica 2000; 66: 444-7
60. Rowlands I, Faughnan M, Hoey L, Wähälä K, Williamson G, Cassidy A. Bioavailability of phytoestrogens. Brit J Nutr 2003; 89: S45-S58
61. Spencer JPE, Abd El Mohsen M, Rice-Evans C. Cellular uptake and metabolism of flavonoids and their metabolites: implication for their bioavailability. Arch Biochem Biophys 2004; 423: 148-61
62. Zeligs MA, Jacobs IC. Compositions and methods of adjusting steroid hormone metabolism through facilitated absorption of hydrophobic dietary compounds. US Patent 6,086,915, 2000.
63. Setchell KD, Zimmer-Nechemias L, Cai J, Heubi JE. Exposure of infants to phyto-oestrogens from soy-based infant formula. Lancet 1997; 350: 23-7
64. Bhat KPL, Pezzuto JM. Natural modulators of estrogen biosynthesis and function as chemopreventive agents. Arch Pharm Res 2001; 24: 73-84
65. Kinghorn AD, Su BN, Jang DS, Chang LC, Lee D, Gu JQ, Carcache-Blanco EJ, Pawlus AD, Lee SK, Park EJ, Cuendet M, Gills JJ, Bhat K, Park HS, Mata-Greenwood E, Song LL, Jang M, Pezzuto JM. Natural inhibitors of carcinogenesis. Planta Medica 2004; 70: 691-705
66. Nicolaou KC, Pfefferkorn JA, Roecker AJ, Cao GQ, Barluenga S, Mitchell HJ. Natural products-like combinatorial libraries based on privileged structures. 1. General principles and solid-phase synthesis of benzopyrans. J Am Chem Soc 2000; 122: 9939-53
67. Reed JM, Potter BVL. Compounds with a sulfamate group. WO 9732872, 1997
68. Reed JM, Potter BVL. Preparation of flavone, isoflavone and flavanone sulfamates as estrone sulfatase and/or aromatase inhibitors for treatment of breast and endometrial cancers. US Patent 6,187,766, 2003
69. Yoshihama M, Nakakoshi M, Nakamura J, Nakayama S. Preparation of novel benzofuranone derivatives as remedies for hormone-dependent diseases. WO 9830556, 1998
70. Hoffren AM, Murray CM, Hoffmann RD. Structure-based focusing using pharmacophores derived from the active site of 17β-hydroxysteroid dehydrogenase. Curr Pharm Des 2001; 7: 547-66
71. Gobec S, Sova M, Kristan K, Rizner TL. Cinnamic acid esters as potent inhibitors of fungal 17β-hydroxysteroid dehydrogenase - a model enzyme of the short-chain dehydrogenase/reductase superfamily. Bioorg Med Chem Lett 2004; 14: 3933-6
72. Yoshihama M, Nakakoshi M, Nakamura J, Nakayama S. Preparation of novel tetralone and benzopyranone derivatives as 17β-HSD inhibitors. WO 9832724, 1998
73. Saarinen NM, Warri A, Makela SI, Eckerman C, Reunanen M, Ahotupa M, Salmi SM, Franke AA, Kangas L, Santti R. Hydroxymatairesinol, a novel enterolactone precursor with antitumor properties from a coniferous tree (Picea abies). Nutr Cancer 2000; 36: 207-14
74. Pouget C, Fagnere C, Basly JP, Habrioux G, Chulia AJ. Design, synthesis and evaluation of 4-imidazolylflavans as new leads for aromatase inhibition. Bioorg Med Chem Lett. 2002; 12: 2859-61
75. Pouget C, Fagnere C, Basly JP, Habrioux G, Chulia AJ. New aromatase inhibitors. Synthesis and inhibitory activity of pyridinyl-substituted flavanone derivatives. Bioorg Med Chem Lett 2002; 12: 1059-61
76. Kim YW, Hackett JC, Brueggemeier RW. Synthesis and aromatase inhibitory activity of novel pyridine-containing isoflavones. J Med Chem 2004; 47: 4032-40
77. Kitaoka M, Kadokawa H, Sugano M, Ichikawa K, Taki M, Takaishi S, Iijima Y, Tsutsumi S, Boriboon M, Akiyama T. Prenylflavonoids: a new class of non-steroidal phytoestrogen (Part 1). Isolation of 8-isopentenylnaringenin and an initial study on its structure-activity relationship. Planta Medica 1998; 64: 511-5
78. Miyamoto M, Matsushita Y, Kiyokawa A, Fukuda C, Iijima Y, Sugano M, Akiyama T. Prenylflavonoids: a new class of non-steroidal phytoestrogen (Part 2). Estrogenic effects of 8-isopentenylnaringenin on bone metabolism. Planta Medica 1998; 64: 516-9
79. Jarry H, Harnischfeger G, Duker E. The endocrine effects of constituents of Cimicifuga racemosa. 2. In vitro binding of constituents to estrogen receptors. Planta Medica 1985; 51: 316-9
80. He K, Zheng B, Kim CH, Rogers L, Zheng Q. Direct analysis and identification of triterpene glycosides by LC/MS in black cohosh, Cimicifuga racemosa, and in several commercially available black cohosh products. Planta Medica 2000;66:635-40
81. Takino Y, Koshioka M, Shiokawa M, Ishii Y, Maruyama S, Higashino M, Hayashi T. Quantitative determination of glycyrrhizic acid in liquorice roots and extracts by TLC-densitometry. Planta Medica 1979; 36: 74-8
82. Liu J, Burdette JE, Xu H, Gu C, van Breemen RB, Bhat KP, Booth N, Constantinou AI, Pezzuto JM, Fong HH, Farnsworth NR, Bolton JL. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J Agric Food Chem 2001; 49: 2472-9
83. Hu K, Yao X. Protodioscin (NSC-698 796): its spectrum of cytotoxicity against sixty human cancer cell lines in an anticancer drug screen panel. Planta Medica 2002; 68: 297-301
84. Lu GH, Chan K, Chan CL, Leung K, Jiang ZH, Zhao ZZ. Quantification Of ligustilides in the roots of Angelica sinensis and related umbelliferous medicinal plants by high-performance liquid chromatography and liquid chromatography-mass spectrometry. J Chromatogr A 2004; 1046: 101-7
85. Makela S, Poutanen M, Lehtimaeki J, Kostian ML, Santti R, Vihko R. Estrogen-specific 17 beta-hydroxysteroid oxidoreductase type 1 (E.C. 1.1.1.62) as a possible target for the action of phytoestrogens. Proc Soc Exp Biol Med 1995; 208: 51-9
86. Coldham NG, Sauer MJ. Identification, quantitation and biological activity of phytoestrogens in a dietary supplement for breast enhancement. Food Chem Toxicol 2001; 39: 1211-24
87. Josephs RA, Guinn JS, Jennifer S, Harper ML, Askari F. Liquorice consumption and salivary testosterone concentrations. Lancet 2001; 358: 1613-4
88. Armanini D, Bonanni G, Mattarello MJ, Fiore C, Sartorato P, Palermo M. Licorice consumption and serum testosterone in healthy man. Exp Clin Endocrinol Diabetes 2003; 111: 341-3
89. Anderson ML. Inhibiting aromatase with specific dietary supplements. US Patent 2004156926, 2004